D
David D. Waters
Researcher at University of California, San Francisco
Publications - 289
Citations - 16543
David D. Waters is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Myocardial infarction & Atorvastatin. The author has an hindex of 62, co-authored 286 publications receiving 15150 citations. Previous affiliations of David D. Waters include San Francisco General Hospital & Montreal Heart Institute.
Papers
More filters
Journal ArticleDOI
American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.
Gary S. Mintz,Steven E. Nissen,William D. Anderson,Steven R. Bailey,Raimund Erbel,Peter J. Fitzgerald,Fausto J. Pinto,Kenneth Rosenfield,Robert J. Siegel,E. Murat Tuzcu,Paul G. Yock,Robert A. O'Rourke,Jonathan Abrams,Eric R. Bates,Bruce R. Brodie,Pamela S. Douglas,Gabriel Gregoratos,Mark A. Hlatky,Judith S. Hochman,Sanjiv Kaul,Cynthia M. Tracy,David D. Waters,William L. Winters +22 more
TL;DR: In this article, the authors present an Expert Consensus Document that includes evidence about the standards for the acquisition, measurement, and reporting of intravascular ultrasound studies (IVUS).
Journal ArticleDOI
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials.
Daniel I. Swerdlow,David Preiss,Karoline Kuchenbaecker,Michael V. Holmes,Jorgen Engmann,Tina Shah,Reecha Sofat,Stefan Stender,Paul C. D. Johnson,Robert A. Scott,Maarten Leusink,Niek Verweij,Stephen J. Sharp,Yiran Guo,Claudia Giambartolomei,Christina Chung,Anne Peasey,Antoinette Amuzu,KaWah Li,Jutta Palmen,Philip N. Howard,Jackie A. Cooper,Fotios Drenos,Yun Li,Gordon D.O. Lowe,John Gallacher,Marlene C. W. Stewart,Ioanna Tzoulaki,Sarah G. Buxbaum,Daphne L. van der A,Nita G. Forouhi,N. Charlotte Onland-Moret,Yvonne T. van der Schouw,Renate B. Schnabel,Jaroslav A. Hubacek,Ruzena Kubinova,Migle Baceviciene,Abdonas Tamosiunas,Andrzej Pajak,Romanvan Topor-Madry,Urszula Stepaniak,Sofia Malyutina,Damiano Baldassarre,Bengt Sennblad,Elena Tremoli,Ulf de Faire,Fabrizio Veglia,Ian Ford,J. Wouter Jukema,Rudi G. J. Westendorp,Gert J. de Borst,Pim A. de Jong,Ale Algra,Wilko Spiering,Anke H. Maitland-van der Zee,Olaf H. Klungel,Anthonius de Boer,Pieter A. Doevendans,Charles B. Eaton,Jennifer G. Robinson,David Duggan,John Kjekshus,John R. Downs,Antonio M. Gotto,Anthony C Keech,Roberto Marchioli,Gianni Tognoni,Peter S. Sever,Neil R Poulter,David D. Waters,Terje R. Pedersen,Pierre Amarenco,Haruo Nakamura,John J.V. McMurray,James Lewsey,Daniel I. Chasman,Paul M. Ridker,Aldo P. Maggioni,Luigi Tavazzi,Kausik K. Ray,Sreenivasa Rao Kondapally Seshasai,JoAnn E. Manson,Jackie F. Price,Peter H. Whincup,Richard W Morris,Debbie A Lawlor,George Davey Smith,Yoav Ben-Shlomo,Pamela J. Schreiner,Myriam Fornage,David S. Siscovick,Mary Cushman,Meena Kumari,Nicholas J. Wareham,W M Monique Verschuren,Susan Redline,Sanjay R. Patel,John C. Whittaker,Anders Hamsten,Joseph A.C. Delaney,Caroline Dale,Tom R. Gaunt,Andrew Wong,Diana Kuh,Rebecca Hardy,Sekar Kathiresan,Berta Almoguera Castillo,Pim van der Harst,Eric J. Brunner,Anne Tybjærg-Hansen,Michael Marmot,Ronald M. Krauss,Michael Y. Tsai,Josef Coresh,Ron C. Hoogeveen,Bruce M. Psaty,Leslie A. Lange,Hakon Hakonarson,Frank Dudbridge,Steve E. Humphries,Philippa J. Talmud,Mika Kivimäki,Nicholas J. Timpson,Claudia Langenberg,Folkert W. Asselbergs,Mikhail Voevoda,Martin Bobak,Hynek Pikhart,James G. Wilson,Alexander P. Reiner,Brendan J. Keating,Aroon D. Hingorani,Naveed Sattar +132 more
TL;DR: The increased risk of type 2 diabetes noted with statins is at least partially explained by HMGCR inhibition.
Journal ArticleDOI
Effect of ACAT inhibition on the progression of coronary atherosclerosis.
Steven E. Nissen,E. Murat Tuzcu,H. Bryan Brewer,Ilke Sipahi,Stephen J. Nicholls,Peter Ganz,Paul Schoenhagen,David D. Waters,Carl J. Pepine,Tim Crowe,Michael H. Davidson,John E. Deanfield,Lisa Wisniewski,James J. Hanyok,Laurent M. Kassalow +14 more
TL;DR: For patients with coronary disease, treatment with an ACAT inhibitor did not improve the primary efficacy variable (percent atheroma volume) and adversely affected two major secondary efficacy measures assessed by intravascular ultrasonography.
Journal ArticleDOI
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.
Prakash Deedwania,Philip J. Barter,Rafael Carmena,Jean Charles Fruchart,Scott M. Grundy,Steven M. Haffner,John J.P. Kastelein,John C. LaRosa,Holly Schachner,James Shepherd,David D. Waters +10 more
TL;DR: These data indicate that patients with coronary heart disease and metabolic syndrome derive incremental benefit from high-dose atorvastatin therapy, irrespective of the presence of diabetes.
Journal ArticleDOI
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease LEADe
Howard Feldman,Rachelle S. Doody,Miia Kivipelto,D L Sparks,David D. Waters,Roy W. Jones,Elias Schwam,Rachel Schindler,Judith Hey-Hadavi,David A. DeMicco,Andrei Breazna +10 more
TL;DR: This study provides Class II evidence that intensive lipid lowering with atorvastatin 80 mg/day in patients with mild to moderate probable Alzheimer disease, taking donepezil, with low-density lipoprotein cholesterol levels between 95 and 195 mg/dL over 72 weeks does not benefit cognition.